Accumulating evidence suggests that CKS2 is an oncoprotein that promotes cancer tumorigenicity and progression, and that CKS2 levels in PTC correlate with the expression of its downstream genes, including cyclin B1 and CDK1. The gene discussed is CKS2; the disease is cancer.